Efficacy and safety of immunotherapy for metastatic renal cell carcinoma: A retrospective study
Authors:
- Marina A. LyadovaMLMarina A. Lyadova
- Denis S. FedorinovDFDenis S. Fedorinov
- Tatiana A. NersesovaTNTatiana A. Nersesova
- Yana V. GridnevaYGYana V. Gridneva
- Maria I. VolkovaMVMaria I. Volkova
- Konstantin V. LyadovKLKonstantin V. Lyadov
- Evgeniya S. KuzminaEKEvgeniya S. Kuzmina
- Tatyana G. AntonovaTATatyana G. Antonova
- Ilya A. PokataevIPIlya A. Pokataev
- Vsevolod N. GalkinVGVsevolod N. Galkin
- Irina V. PoddubnayaIPIrina V. Poddubnaya
Open Access
- 4 May 2025
- journal article
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (1) , 36-41
Abstract
Aim. To evaluate the efficacy and safety of immune checkpoint inhibitors in patients with metastatic renal cell carcinoma (RCC) in the Russian patient population. Materials and methods. This retrospective study included 231 patients (157 males and 74 females) aged 44 to 86 years (median 64.56±8.09) who underwent examination and treatment at Moscow City Hospital named after S.S. Yudin and Moscow Center for Rehabilitation Treatment. Results. The median follow-up was 16.6 months (13.38-18.61). The effectiveness of therapy was evaluated in all patients included in the study. Objective response (complete regression + partial regression) was achieved in 45 (19.5%) patients. Disease control (objective response + stabilization) was reported in 186 (80.5%) subjects. Median of overall survival in patients with metastatic RCC was 15.62 months (95% confidence interval [CI] 12.89-17.75): in the 1st line group, 13.18 months (95% CI 11.21-17.75), and in the 2nd and subsequent lines group, 16.72 months (95% CI 13.41-20.19). Grade 1-2 immune-mediated adverse events were reported in 81.8% (n=189) of patients, of which 97 (78.9%) received 1st line immunotherapy and 92 (85.2%) received 2nd and subsequent lines. Conclusion. RCC immunotherapy in the Russian population is associated with high rates of objective response and disease control in the first line of treatment (19.5 and 80.5%, respectively). This treatment method is typically associated with a small number of grade 3-4 immune-mediated adverse events (3.03% according to our data), which indicates an acceptable safety profile and is comparable with the data from foreign studies.Keywords
This publication has 23 references indexed in Scilit:
- Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinomaCancer, 2022
- Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920Cancer, 2021
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trialThe Lancet Oncology, 2020
- 710P Phase II trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analysesAnnals of Oncology, 2020
- Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trialCancer, 2020
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With NivolumabJAMA Oncology, 2019
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2018
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trialThe Lancet Oncology, 2018
- The diverse functions of the PD1 inhibitory pathwayNature Reviews Immunology, 2017
- Comprehensive Molecular Characterization of Papillary Renal-Cell CarcinomaNew England Journal of Medicine, 2016